Gabapentin, used in the treatment of epilepsy and neuropathic pain, preferentially binds to α2δ1/2 and lowers α2δ surface expression, demonstrating that the α2δ auxiliary subunit is a druggable target [[62], [63], [64]]. The gene discussed is ATXN2L; the disease is epilepsy.